Tesla Cybercab Is Finally Moving. The Stock Still Needs Robotaxi Economics.
Tesla is preparing its Cybercab rollout while capex surges and auto margins stay weak. I examine what robotaxi economics must deliver to justify the valuation.
- August 20, 2026
- by Novalis
- 9 minutes read
- 134 Views
Nvidia’s $105 Billion OpenAI Guarantee: When Chip Demand Starts Financing Itself
Nvidia may guarantee up to $105 billion for an OpenAI data-center lease. I examine what this says about AI demand, circular financing and Nvidia’s valuation.
- August 20, 2026
- by Novalis
- 12 minutes read
- 137 Views
Why Rising Bond Yields Hit Tech Stocks So Hard: A Practical Duration Guide
Long-term bond yields are rising and tech stocks are selling off. Here is the valuation math behind duration, discount rates and why growth shares react so violently.
- August 20, 2026
- by Novalis
- 11 minutes read
- 118 Views
Amazon: AWS Is Accelerating. The AI Capex Bill Is Accelerating Faster.
AWS growth accelerated sharply in Q2, but Amazon’s AI infrastructure spending pushed free cash flow negative. I examine whether the investment cycle is creating enough value.
- August 20, 2026
- by Novalis
- 13 minutes read
- 102 Views
Nvidia Stock After Q2 FY2027: $96 Billion of Revenue—and the Working-Capital Shadow
Nvidia’s Q2 FY2027 revenue reached $96.2 billion. A close look at margins, cash conversion, AI financing, China risk and the $5.09 trillion valuation.
- August 20, 2026
- by Novalis
- 10 minutes read
- 112 Views
Marvell’s Google AI Chip Deal Is Huge. The Dilution Is the Price of Admission.
Google’s custom-AI-chip agreement could generate enormous revenue for Marvell, but the warrant can also dilute shareholders. I examine what the deal is really worth.
- August 20, 2026
- by Novalis
- 11 minutes read
- 118 Views
Tesla’s Cybercab Launch Is the Test the Valuation Can No Longer Avoid
Tesla is preparing a broader Cybercab rollout while auto margins remain thin and AI spending rises. I examine what robotaxi economics must deliver to justify the valuation.
- August 20, 2026
- by Novalis
- 12 minutes read
- 100 Views
Moderna’s Cancer Vaccine Breakthrough Is Real. The Valuation Is Now the Harder Question.
Moderna’s personalized cancer vaccine just delivered the kind of Phase 3 result the mRNA platform needed. The science looks far more credible today. The stock price, however, now asks a.
- August 13, 2026
- by Novalis
- 9 minutes read
- 109 Views
Cisco: AI Has Revived One of Technology’s Oldest Giants
THE CAPITAL · STOCK ANALYSIS · AUGUST 13, 2026 Cisco just reported $17.3 billion of quarterly revenue, $9.3 billion of full-year AI infrastructure orders and a fiscal 2027 outlook far.
- August 12, 2026
- by Novalis
- 14 minutes read
- 153 Views
CoreWeave: The AI Boom Has Found Its Most Leveraged Business Model
The Capital · Stock Analysis · August 12, 2026 CoreWeave doubled quarterly revenue, ended June with roughly $104 billion of backlog and added more than $25 billion of new customer.
